<DOC>
	<DOCNO>NCT00185315</DOCNO>
	<brief_summary>The aim study monitor long-term safety tolerability iloprost aerosol inhalation therapy patient suffer pulmonary hypertension .</brief_summary>
	<brief_title>Safety Follow-up Study Inhaled Iloprost Patients With Pulmonary Hypertension</brief_title>
	<detailed_description>This study previously post Schering AG , Germany . Schering AG rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Completion 12week treatment period predecessor Schering study 97218/300180 Investigator judge iloprost aerosol therapy warrant suitable treatment respective patient Negative pregnancy test females Any condition 12week treatment period predecessor Schering study 97218/300180 prevents participation followup safety surveillance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>